Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts
Language English Country Great Britain, England Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
16428939
DOI
10.1097/00001813-200602000-00012
PII: 00001813-200602000-00012
Knihovny.cz E-resources
- MeSH
- Amantadine analogs & derivatives therapeutic use MeSH
- Drug Resistance, Neoplasm MeSH
- Cisplatin adverse effects MeSH
- Ligands MeSH
- Mice, Nude MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Prostatic Neoplasms drug therapy pathology prevention & control MeSH
- Colonic Neoplasms drug therapy pathology prevention & control MeSH
- Ovarian Neoplasms drug therapy pathology prevention & control MeSH
- Organoplatinum Compounds therapeutic use MeSH
- Antineoplastic Agents therapeutic use MeSH
- Transplantation, Heterologous MeSH
- Cell Survival drug effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Amantadine MeSH
- bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) MeSH Browser
- Cisplatin MeSH
- Ligands MeSH
- Organoplatinum Compounds MeSH
- Antineoplastic Agents MeSH
- satraplatin MeSH Browser
The oral anti-tumor activity of a novel platinum(IV) complex, coded as LA-12, with a bulky adamantylamine ligand was evaluated and compared with another platinum(IV) complex satraplatin. The human carcinoma xenografts of colon HCT116, prostate PC3, and ovarian A2780 and A2780/cisR (resistant to cisplatin) were used to evaluate the in-vivo anti-tumor activity. The daily x 5 repeated dose regimen in equimolar doses of LA-12 and satraplatin, administered in 2 cycles, was selected for this evaluation. All doses of LA-12 and satraplatin were significantly effective in comparison with the control. The activities of LA-12 in all doses and all used tumor xenografts were higher than equimolar doses of satraplatin. The highest effect was reached with LA-12 at a dose of 60 mg/kg. The shapes of growth curves of ovarian carcinoma A2780 and its subline resistant to cisplatin after therapy with LA-12 were very similar. This shows that LA-12 is able to overcome resistance to cisplatin.
References provided by Crossref.org
The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo
